Antimicrobial resistance grant
This article was originally published in The Rose Sheet
Executive SummaryCenters for Disease Control & Prevention announces availability of roughly $600,000 in grant funding for fiscal 2002 for applied research aimed at "prevention and control of the emergence and spread of antimicrobial resistance" in the U.S. Program will focus on validation of national committee for clinical laboratory standards (NCCLS) breakpoints for human pathogens of public health importance, according to June 4 Federal Register notice. Research expected to begin Aug. 30 and continue for up to three years. Completed application forms, available at 1CDC's Web site, are due July 16...
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”